Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 100Breast Neoplasms 74Fallopian Tube Neoplasms 47Multiple Myeloma 32Carcinoma, Ovarian Epithelial 27Neoplasms 23Lymphoma 15Triple Negative Breast Neoplasms 12Sarcoma 12Recurrence 12Neoplasm Metastasis 12Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Non-Hodgkin 8Hodgkin Disease 8Neoplasms, Plasma Cell 6Prostatic Neoplasms 5Burkitt Lymphoma 5Solid Tumors 4Sarcoma, Kaposi 4Sarcoma, Ewing 4Pancreatic Neoplasms 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Mantle-Cell 4Leiomyosarcoma 4Endometrial Neoplasms 4Carcinoma 4Breast Neoplasms, Male 4Uterine Cervical Neoplasms 3Rhabdomyosarcoma 3Peritoneal Neoplasms 3

Interventions

niraparib 3Paclitaxel 2Letrozole 2trametinib 1ribociclib 1pembrolizumab 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Doxorubicin 1Diphenhydramine 1Dexamethasone 1Cimetidine 1CTLA-4 Antigen 1Blood Specimen Collection 1Axitinib 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cystadenocarcinoma, Serous × liposomal doxorubicin × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡